AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company that completed its de-SPAC merger with Priveterra Acquisition Corp. in August 2023, with Priveterra Management LLC serving as sponsor on the blank-check vehicle that conducted its IPO in 2021. The company is focused on botulinum toxin therapeutics, advancing its lead candidate AB-001 across multiple therapeutic indications. AEON has been an active Nasdaq-listed reporting company since the merger closed, filing the present Form 8-K with the SEC on January 21, 2026. The company operates in the specialty biopharmaceuticals sector. Sign up for SpacDesk to access the full data profile, filing history, and real-time analytics on AEON and hundreds of other SPAC-origin companies.